Aldeyra (NASDAQ: ALDX) shifts RASP to ADX-248/246; INDs in 2026, runway to 2027

Aldeyra Therapeutics Breakthrough in Alcohol-Associated Hepatitis Treatment Highlights Future Focus

In an exciting development for the treatment of alcohol-associated hepatitis, Aldeyra Therapeutics, Inc., a biotechnology company based in Lexington, Massachusetts, has announced promising results from a Phase 2 clinical trial involving their investigational drug candidate, ADX-629. As part of their broader mission to combat immune-mediated diseases, this advancement serves as a significant milestone for the company. ADX-629 is a reactive aldehy…

Aldeyra (NASDAQ: ALDX) shifts RASP to ADX-248/246; INDs in 2026, runway to 2027

Phase 2 ADX‑629 study (n=4, 1 month) improved MELD, triglycerides, CRP; no serious AEs. Pipeline to ADX‑248/246, INDs in 2026; runway into H2 2027.